Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma
Melissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, Rita E Chen, Coley Doolittle-Amieva, George Ansstas, Shailender Bhatia, Evan T Hall, Paul T Nghiem, Song Y Park, David Y Chen · 2025
Read Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma by Melissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, Rita E Chen, Coley Doolittle-Amieva, George Ansstas, Shailender Bhatia, Evan T Hall, Paul T Nghiem, Song Y Park, David Y Chen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742145.txt.
Description
Melissa Yamada and co-authors review what an engineered virus therapy achieves as a last-line treatment for advanced melanoma in everyday practice. Their 2025 study covers talimogene laherparepvec, a modified herpes virus injected into tumors. Trial approval is one thing; the clinic's patients arrive heavily pretreated, where the evidence runs thin.
Records covered 121 patients treated from 2015 to 2024. Nearly nine in ten had already had systemic therapy, and a third carried both injectable and unreachable disease. Median survival without progression ran about a year, and overall survival near three years. Two thirds of those scored responded, a third completely. The team models which clinical traits sway the outcome.
Catalog record
| CREATOR | Melissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, Rita E Chen, Coley Doolittle-Amieva, George Ansstas, Shailender Bhatia, Evan T Hall, Paul T Nghiem, Song Y Park, David Y Chen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |